165 related articles for article (PubMed ID: 35243663)
1. Ten-eleven translocation-2 inactivation restrains IL-10-producing regulatory B cells to enable antitumor immunity in hepatocellular carcinoma.
Lu Z; Liu R; Wang Y; Jiao M; Li Z; Wang Z; Huang C; Shi G; Ke A; Wang L; Fu Y; Xia J; Wen H; Zhou J; Wang X; Ye D; Fan J; Chu Y; Cai J
Hepatology; 2023 Mar; 77(3):745-759. PubMed ID: 35243663
[TBL] [Abstract][Full Text] [Related]
2. Global DNA 5-Hydroxymethylcytosine and 5-Formylcytosine Contents Are Decreased in the Early Stage of Hepatocellular Carcinoma.
Liu J; Jiang J; Mo J; Liu D; Cao D; Wang H; He Y; Wang H
Hepatology; 2019 Jan; 69(1):196-208. PubMed ID: 30070373
[TBL] [Abstract][Full Text] [Related]
3. Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1
Ye L; Zhang Q; Cheng Y; Chen X; Wang G; Shi M; Zhang T; Cao Y; Pan H; Zhang L; Wang G; Deng Y; Yang Y; Chen G
J Immunother Cancer; 2018 Dec; 6(1):145. PubMed ID: 30526680
[TBL] [Abstract][Full Text] [Related]
4. Induction of active demethylation and 5hmC formation by 5-azacytidine is TET2 dependent and suggests new treatment strategies against hepatocellular carcinoma.
Sajadian SO; Ehnert S; Vakilian H; Koutsouraki E; Damm G; Seehofer D; Thasler W; Dooley S; Baharvand H; Sipos B; Nussler AK
Clin Epigenetics; 2015; 7(1):98. PubMed ID: 26366235
[TBL] [Abstract][Full Text] [Related]
5. Role of ten-eleven translocation proteins and 5-hydroxymethylcytosine in hepatocellular carcinoma.
Wang P; Yan Y; Yu W; Zhang H
Cell Prolif; 2019 Jul; 52(4):e12626. PubMed ID: 31033072
[TBL] [Abstract][Full Text] [Related]
6. FGFR3
Jin Z; Feng H; Liang J; Jing X; Zhao Q; Zhan L; Shen B; Cheng X; Su L; Qiu W
Cell Death Dis; 2020 Oct; 11(10):903. PubMed ID: 33097695
[TBL] [Abstract][Full Text] [Related]
7. PD-1hi Identifies a Novel Regulatory B-cell Population in Human Hepatoma That Promotes Disease Progression.
Xiao X; Lao XM; Chen MM; Liu RX; Wei Y; Ouyang FZ; Chen DP; Zhao XY; Zhao Q; Li XF; Liu CL; Zheng L; Kuang DM
Cancer Discov; 2016 May; 6(5):546-59. PubMed ID: 26928313
[TBL] [Abstract][Full Text] [Related]
8. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.
Liu H; Shen J; Lu K
Biochem Biophys Res Commun; 2017 Apr; 486(2):239-244. PubMed ID: 28254435
[TBL] [Abstract][Full Text] [Related]
9. Dynamic analysis of tumor-associated immune cells in DEN-induced rat hepatocellular carcinoma.
Song S; Yuan P; Li P; Wu H; Lu J; Wei W
Int Immunopharmacol; 2014 Oct; 22(2):392-9. PubMed ID: 25066760
[TBL] [Abstract][Full Text] [Related]
10. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
[TBL] [Abstract][Full Text] [Related]
11. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
12. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
[TBL] [Abstract][Full Text] [Related]
13. The TET2/E-cadherin/β-catenin regulatory loop confers growth and invasion in hepatocellular carcinoma cells.
Yang G; Zeng X; Wang M; Wu A
Exp Cell Res; 2018 Feb; 363(2):218-226. PubMed ID: 29331390
[TBL] [Abstract][Full Text] [Related]
14. Structural insight into substrate preference for TET-mediated oxidation.
Hu L; Lu J; Cheng J; Rao Q; Li Z; Hou H; Lou Z; Zhang L; Li W; Gong W; Liu M; Sun C; Yin X; Li J; Tan X; Wang P; Wang Y; Fang D; Cui Q; Yang P; He C; Jiang H; Luo C; Xu Y
Nature; 2015 Nov; 527(7576):118-22. PubMed ID: 26524525
[TBL] [Abstract][Full Text] [Related]
15. DNA methylcytosine dioxygenase ten-eleven translocation 2 enhances lipopolysaccharide-induced cytokine expression in human dental pulp cells by regulating MyD88 hydroxymethylation.
Wang X; Feng Z; Li Q; Yi B; Xu Q
Cell Tissue Res; 2018 Aug; 373(2):477-485. PubMed ID: 29654353
[TBL] [Abstract][Full Text] [Related]
16. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-35 has a tumor-promoting role in hepatocellular carcinoma.
Liu X; Ren H; Guo H; Wang W; Zhao N
Clin Exp Immunol; 2021 Feb; 203(2):219-229. PubMed ID: 33030251
[TBL] [Abstract][Full Text] [Related]
18. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
Zhang W; Liu Y; Yan Z; Yang H; Sun W; Yao Y; Chen Y; Jiang R
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581055
[TBL] [Abstract][Full Text] [Related]
19. Decrease of 5-hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1.
Liu C; Liu L; Chen X; Shen J; Shan J; Xu Y; Yang Z; Wu L; Xia F; Bie P; Cui Y; Bian XW; Qian C
PLoS One; 2013; 8(5):e62828. PubMed ID: 23671639
[TBL] [Abstract][Full Text] [Related]
20. Targeting Histone Deacetylase 6 Reprograms Interleukin-17-Producing Helper T Cell Pathogenicity and Facilitates Immunotherapies for Hepatocellular Carcinoma.
Qiu W; Wang B; Gao Y; Tian Y; Tian M; Chen Y; Xu L; Yao TP; Li P; Yang P
Hepatology; 2020 Jun; 71(6):1967-1987. PubMed ID: 31539182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
